Local pharmaceutical manufacturer Adcock Ingram says its push into non-regulated products where it has better pricing power is paying off, but it is looking for growth across all its business divisions even as it grapples with pandemic-induced shifts in consumer spending.        

The group, in which Bidvest has a controlling stake, has been bulking up its presence in areas such as shoe-care products, a move that has helped the revenue contribution from products that are not price regulated rise from about a third to just under half over the past two years...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.